Pfizer and BioNTech initiate omicron-specific vaccine trial for adults under 55
Pfizer and BioNTech begin a clinical trial to assess the safety and immune response of an omicron-specific COVID-19 vaccine in adults under 55 years of age.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthPfizer and BioNTech initiate omicron-specific vaccine trial for adults under 55
Sign in or subscribeBrowse free archive reportsPfizer and BioNTech begin a clinical trial to assess the safety and immune response of an omicron-specific COVID-19 vaccine in adults under 55 years of age.